Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Genetic Variants in Epilepsy Gene Identified
Disease Discoveries

Genetic Variants in Epilepsy Gene Identified

By Melissa RohmanJun 6, 2022
Share
Facebook Twitter Email
Gemma Carvill, PhD, assistant professor in The Ken and Ruth Davee Department of Neurology Division of Epilepsy and Clinical Neurophysiology, of Pediatrics, and of Pharmacology, was senior author of the study published in Brain.

Investigators have discovered a new method to determine whether individual genetic variants in the epilepsy-associated gene SZT2 cause a neurodevelopmental disorder, according to a Northwestern Medicine study published in the journal Brain.

Pathogenic variants in SZT2 have been associated with the development of different neurodevelopmental disorders, including early-onset epilepsy and developmental delays. Additionally, the SZT2 protein plays an essential role in the mTORC1 signaling pathway, which helps promote cell growth and proliferation.

Meanwhile, many SZT2 missense variants — variants where a single amino acid is replaced by another — have been increasingly detected through clinical genetic testing but classified as variants of uncertain significance, or variants that do not have a clear association with disease.

Classifying these variants as either likely benign or pathogenic, however, has remained a challenge due the large size of SZT2 — it contains more than 3,400 amino acids — as well as its lack of crystal structure and functional domains.

“There are many different amino acids that can be mutated and become missense variants, so it’s very challenging to tell which are pathogenic and which are benign. That’s why high-throughput studies like this are so important,” said Gemma Carvill, PhD, assistant professor in The Ken and Ruth Davee Department of Neurology Division of Epilepsy and Clinical Neurophysiology and senior author of the study.

For the current study, Carvill’s team recruited twelve individuals who carried biallelic SZT2 variants of which one or more were classified as variants of uncertain significance.

Using CRISPR-Cas9 genome editing, the investigators engineered cells to contain patient-specific missense SZT2 variants and performed a functional cell assay that separated cells based on whether the mTORC1 signaling pathway was active or inactive.

The investigators then used next-generation sequencing to determine which SZT2 missensevariants retained function and which lost function and were likely to be pathogenic.

Ultimately, they discovered a recurrent in-frame deletion — when one amino acid is deleted out of the protein — and was determined to be a loss-of-function variant and reclassified as likely pathogenic.

Jeffrey Calhoun, PhD, research assistant professor of Neurology Division of Epilepsy and Clinical Neurophysiology, was lead author of the study.

This recurrent variant is also a founder variant, a genetic variant that occurs more prevalently in individuals with similar or the same ethnicity. In this case, the founder variant is more prevalent in individuals of Ashkenazi Jewish ancestry, and this variant should be included in targeted panels for individuals interested in prenatal testing, according to Carvill.

The current approach is applicable to other neurodevelopmental disorders that are rooted in the mTOR pathway, according to the authors.

Furthermore, mTOR inhibitors may benefit patients with genetic variants affecting mTOR function. Only recently has SZT2 been associated with this particular pathway, as compared to other epilepsy-associated mTOR genes, warranting a need for future clinical trials and high-throughput cell assays.

“In the future, it is key that we design trials where we specifically enroll individuals that have a positive genetic test in mTOR pathway genes to see if those patients may benefit from mTOR inhibition,” said Jeffrey Calhoun, PhD, research assistant professor of Neurology Division of Epilepsy and Clinical Neurophysiology and lead author of the study.

This study was first initiated through a collaboration with Elizabeth Gerard, MD, associate professor of Neurology in the Division of Epilepsy and Clinical Neurophysiology. Carvill and Gerard are co-directors of the Adult Epilepsy Genetics Clinic at Northwestern.

Co-authors of the study include Hannah Happ, a student in the Driskill Graduate Program in Life Sciences (DGP); Emily Bryant, MS, instructor of Pediatrics in the Division of Genetics, Birth Defects and Metabolism; Divakar Mithal, ’13 MD, ’11 PhD, ’15, ’18 GME, instructor of Pediatrics in the Division of Neurology and Epilepsy; Lisa Kinsley, MS, assistant professor of Neurology; Issam Ben-Sahra, PhD, assistant professor of Biochemistry and Molecular Genetics; John Joseph Millichap, MD, ’10, ’11 GME, adjunct associate professor of Neurology in the Division of Epilepsy and Clinical Neurophysiology; and

This work was supported by National Institute of Neurological Disorders and Stroke grant R00NS089858. and the Northwestern University Clinical and Translational Sciences (NUCATS) Institute grant TR001423.

Genetics Neurology Research
Share. Facebook Twitter Email

Related Posts

Understanding How Hormones Influence Anemia

May 25, 2023

Groundbreaking Geneticist Delivers Epigenetics Lecture

May 24, 2023

CT Scan Best at Predicting Heart Disease Risk in Middle Age

May 23, 2023

Comments are closed.

Latest News

Celebrating Advances in Alzheimer’s Research and Clinical Care

May 26, 2023

Understanding How Hormones Influence Anemia

May 25, 2023

Groundbreaking Geneticist Delivers Epigenetics Lecture

May 24, 2023

CT Scan Best at Predicting Heart Disease Risk in Middle Age

May 23, 2023

Investigating the Benefits of Salt Substitutes in Elderly Patients

May 22, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230506_NM569
20230506_NM564
20230506_NM563
20230506_NM559
20230506_NM555
20230506_NM549
20230506_NM508
20230506_NM474
20230506_NM136
20230506_NM124
20230506_NM118
20230506_NM094

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.